Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

LabCentral 238 has secured $12.5m from founding sponsor Astellas, which will also provide capital for LabCentral's existing incubator.

The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

Novo Holdings co-led a series C round for orthodontic brace technology developer Swift Health Systems, which has now raised more than $70m.

Ajax Health has led a $25m series A round for medical device manufacturer EP Map System.

University of Oxford-founded autoimmune disease therapy developer MiroBio has launched with support from OSI and GlaxoSmithKline’s SR One.

University of Oxford-founded autoimmune disease therapy developer MiroBio has launched with support from GlaxoSmithKline subsidiary SR One.

LG Technology Ventures and existing investors Novo, SR One and Takeda Ventures all took part in a round that will support the advance of Arcellx's immuno-oncology cell therapies.